Duloxetine Viatris (previously Duloxetine Mylan) (duloxetine)
Generic
- Region
- 🇪🇺 EU
- Active substance
- duloxetine
- Company
- Viatris Limited
- Status
- Authorised
- Therapeutic area
- Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major; Anxiety Disorders
- CHMP opinion
- Thu 23 Apr 2015
- EU approval
- Fri 19 Jun 2015
- Designations
- Generic
- Application
- EMEA/H/C/003981
- ATC
- N06AX21
- Official record
- www.ema.europa.eu
Indication
Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Viatris is indicated in adults
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Duloxetine Hydrochloride Approved · Almatica
- 🇪🇺 Duloxetine Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Duloxetine Lilly Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Cymbalta Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Yentreve Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Nodetrip (previously Xeristar) Withdrawn · Esteve Pharmaceuticals, S.A.
- 🇪🇺 Ariclaim Withdrawn · Eli Lilly Nederland B.V.
- 🇪🇺 Duloxetine Sandoz Application withdrawn · Sandoz GmbH
- 🇪🇺 Duloxetine Boehringer Ingelheim Withdrawn · Boehringer Ingelheim International GmbH
Follow Duloxetine Viatris (previously Duloxetine Mylan)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.